Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.49 |
| ▸ | PLK1 | P53350 | 13/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873174 | 0.86 | KDR (0.49) | KDRPLK1 | |
| SCHEMBL6875858 | 0.86 | KDR (0.52) | KDRPLK1INSR | |
| SCHEMBL6876249 | 0.86 | GABRG2 (0.46) | KDRPLK1INSR | |
| SCHEMBL6864911 | 0.84 | KDR (0.54) | KDRPLK1INSR | |
| SCHEMBL6873283 | 0.83 | KDR (0.60) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL6864750 | 0.80 | KDR (0.50) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL6872526 | 0.78 | KDR (0.48) | KDRPLK1INSR | |
| SCHEMBL16270731 | 0.73 | PLK1 (0.72) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL6873778 | 0.72 | KDR (0.55) | KDRPLK1INSR | |
| SCHEMBL12217717 | 0.72 | PLK1 (0.58) | KDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399448-B1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1399448-A1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6686352-B2 | USEFUL AS COGNITIVE ENHANCER OR FOR THERAPY OF COGNITIVE DISORDERS LIKE ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094834-A1 | IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | GALR1, GALR2, ADRA1A | KDR 1308/4885PLK1 4198/4885INSR 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.